Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Neil Lerner, the Chief Accounting Officer of Compass Therapeutics, Inc. (NASDAQ:CMPX), has recently acquired 20,000 shares of the company's common stock. The purchase comes as the stock has declined nearly 30% over the past week, according to InvestingPro data. The shares were purchased at a weighted average price of $1.42, with the total transaction amounting to $28,400. Following this acquisition, Lerner's total direct ownership in the company stands at 320,000 shares. This transaction was executed on April 7, 2025, as per the latest SEC filing. The $217 million market cap company maintains strong liquidity with a current ratio of nearly 15x and holds more cash than debt on its balance sheet. InvestingPro analysis reveals 8 additional key insights about CMPX's financial health and growth prospects.
In other recent news, Compass Therapeutics announced positive results from its COMPANION-002 Phase 2/3 trial, which evaluated the combination of tovecimig and paclitaxel in treating advanced biliary tract cancer. The combination therapy showed a statistically significant improvement in overall response rate compared to paclitaxel alone, with a notable increase to 17.1% from 5.3%. Additionally, Compass Therapeutics has been the focus of several analyst reports. Leerink Partners upgraded the company's stock rating to Outperform, raising the price target to $6.00 due to a positive outlook on its clinical programs. Meanwhile, Stifel maintained a Buy rating with a $10.00 target, expressing confidence in the company's risk/reward balance. Piper Sandler initiated coverage with an Overweight rating and a $12.00 target, highlighting the upcoming data readout from the COMPANION-002 trial as a potential catalyst. Compass Therapeutics also reported progress on other cancer treatments, including the advancement of CTX-10726 and preparations for Phase 2 biomarker trials. The company ended 2024 with an estimated $127 million in cash and marketable securities, expected to fund operations into early 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.